Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by Macquarie Group Ltd.

Macquarie Group Ltd. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,012 shares of the biopharmaceutical company’s stock after selling 2,649 shares during the quarter. Macquarie Group Ltd.’s holdings in Alnylam Pharmaceuticals were worth $1,529,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ALNY. FMR LLC increased its stake in Alnylam Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after acquiring an additional 815,270 shares during the last quarter. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after acquiring an additional 759,295 shares during the last quarter. BlackRock Inc. increased its stake in Alnylam Pharmaceuticals by 9.3% in the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after acquiring an additional 441,957 shares during the last quarter. Baillie Gifford & Co. increased its stake in Alnylam Pharmaceuticals by 2.9% in the second quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after acquiring an additional 96,805 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in Alnylam Pharmaceuticals by 25.3% in the third quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock valued at $92,185,000 after acquiring an additional 158,288 shares during the last quarter. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $128.73 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. Alnylam Pharmaceuticals, Inc. has a 1 year low of $35.98 and a 1 year high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same quarter in the previous year, the company earned ($1.21) earnings per share. The business’s quarterly revenue was up 24.8% on a year-over-year basis. research analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current fiscal year.

A number of research analysts recently commented on ALNY shares. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Jefferies Group set a $102.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. BidaskClub cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 16th. Credit Suisse Group reissued a “buy” rating and issued a $96.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 11th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $56.00 target price (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $121.85.

In other news, SVP Laurie Keating sold 30,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the sale, the senior vice president now directly owns 41,500 shares in the company, valued at $5,639,435. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Barry E. Greene sold 76,815 shares of the stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the sale, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 393,212 shares of company stock valued at $48,109,436. Company insiders own 4.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by Macquarie Group Ltd.” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/12/08/alnylam-pharmaceuticals-inc-alny-shares-sold-by-macquarie-group-ltd.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply